Quick Answer
Harmony Biosciences Holdings, Inc. reported Total Revenue of $868.45 million for the year ending 2025.
- Harmony Biosciences Holdings, Inc. showed an increase of +21.5% in Total Revenue from 2024 to 2025.
- This data is from Harmony Biosciences Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $19.84 million | Q2 2020: $38.01 million | Q3 2020: $45.61 million | Q1 2021: $59.67 million | Q2 2021: $73.82 million | Q3 2021: $80.73 million | Q1 2022: $85.31 million | Q2 2022: $107.03 million | Q3 2022: $117.21 million | Q1 2023: $119.13 million | Q2 2023: $134.22 million | Q3 2023: $160.27 million | Q1 2024: $154.62 million | Q2 2024: $172.81 million | Q3 2024: $186.04 million | Q1 2025: $184.73 million | Q2 2025: $200.49 million | Q3 2025: $239.46 million.
- Over the full 7 years of available data (2019 to 2025), Harmony Biosciences Holdings, Inc.'s Total Revenue has grown by 14,386.3%.
- Historical annual values: Fiscal year 2025: $868.45 million | Fiscal year 2024: $714.73 million | Fiscal year 2023: $582.02 million | Fiscal year 2022: $437.86 million | Fiscal year 2021: $305.44 million | Fiscal year 2020: $159.74 million | Fiscal year 2019: $6.00 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: